|
End-of-day quote
New Zealand S.E.
2026-08-18
|
5-day change | 1st Jan Change | ||
| 4.250 NZD | -1.16% |
|
-6.18% | +25.74% |
| 07-31 | AFT Pharmaceuticals Limited - Shareholder/Analyst Call | |
| 07-31 | New Zealand Shares Fall; AFT Pharmaceuticals Chair to Retire | MT |
Company Valuation: AFT Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 378 | 362.8 | 328.2 | 282.1 | 352.4 | 445.7 | - | - |
| Change | - | -4% | -9.54% | -14.06% | 24.91% | 26.5% | - | - |
| Enterprise Value (EV) 1 | 407.3 | 392.7 | 344.4 | 296.6 | 391 | 475.6 | 470.3 | 465.9 |
| Change | - | -3.57% | -12.3% | -13.89% | 31.82% | 21.64% | -1.1% | -0.95% |
| P/E | 19x | 34.6x | 20.9x | 24.5x | 24x | 22.6x | 18x | 16.8x |
| PBR | 6.66x | 4.95x | 3.74x | 2.89x | 3.2x | 4.87x | 4.06x | 3.35x |
| PEG | - | -0.7x | 0.4x | -0.9x | 0.9x | 0.7x | 0.7x | 2.38x |
| Capitalization / Revenue | 2.9x | 2.32x | 1.68x | 1.36x | 1.38x | 1.47x | 1.29x | 1.14x |
| EV / Revenue | 3.13x | 2.51x | 1.76x | 1.43x | 1.53x | 1.57x | 1.36x | 1.19x |
| EV / EBITDA | 19x | 18.4x | 13.1x | 14.2x | 13.6x | 13.7x | 11.4x | 9.33x |
| EV / EBIT | 20x | 20x | 14.2x | 16.8x | 16x | 15.5x | 12.7x | 10.3x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.016 | 0.018 | 0.025 | 0.0328 | 0.0416 | 0.0652 |
| Rate of return | - | - | 0.51% | 0.67% | 0.74% | 0.77% | 0.98% | 1.53% |
| EPS 2 | 0.19 | 0.1 | 0.15 | 0.11 | 0.14 | 0.1878 | 0.2366 | 0.2533 |
| Distribution rate | - | - | 10.7% | 16.4% | 17.9% | 17.4% | 17.6% | 25.7% |
| Net sales 1 | 130.3 | 156.6 | 195.4 | 208 | 254.7 | 303.8 | 345.2 | 392.5 |
| EBITDA 1 | 21.43 | 21.39 | 26.25 | 20.88 | 28.8 | 34.63 | 41.41 | 49.9 |
| EBIT 1 | 20.39 | 19.67 | 24.24 | 17.65 | 24.44 | 30.64 | 37.05 | 45.17 |
| Net income 1 | 19.85 | 10.65 | 15.61 | 11.96 | 14.73 | 19.7 | 24.81 | 26.56 |
| Net Debt 1 | 29.3 | 29.9 | 16.2 | 14.5 | 38.6 | 29.84 | 24.6 | 20.14 |
| Reference price 2 | 3.610 | 3.460 | 3.130 | 2.690 | 3.360 | 4.250 | 4.250 | 4.250 |
| Nbr of stocks (in thousands) | 104,697 | 104,866 | 104,866 | 104,866 | 104,866 | 104,875 | - | - |
| Announcement Date | 5/22/22 | 5/22/23 | 5/22/24 | 5/21/25 | 5/20/26 | - | - | - |
1NZD in Million2NZD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 22.63x | 1.57x | 13.73x | 0.77% | 262M | |
| 35.07x | 12.64x | 25.79x | 0.56% | 1,093B | |
| 30.16x | - | - | 1.98% | 653B | |
| 33.05x | 7.66x | 15.93x | 2.65% | 458B | |
| 20.11x | 4.77x | 11.83x | 2.77% | 355B | |
| 21.93x | 5.66x | 14.07x | 2.83% | 294B | |
| 20.48x | 4.23x | 12x | 2.08% | 248B | |
| 26.9x | 6.98x | 12.39x | 2.37% | 230B | |
| 13.48x | 4.8x | 10.06x | 3.81% | 203B | |
| -43.83x | 6.34x | 24.76x | 2.3% | 178B | |
| Average | 18.00x | 6.07x | 15.62x | 2.21% | 371.07B | |
| Weighted average by Cap. | 25.04x | 8.32x | 18.34x | 1.93% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AFT Stock
- Valuation AFT Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
